ESMO26: Toni Choueiri, MD, on KEYNOTE-564 | Dana-Farber Cancer Institute
RCC Content Hub
Final analysis of the pivotal KEYNOTE-564 trial in kidney cancer presented by Toni Choueiri, MD, of Dana-Farber Cancer Institute at #ESMO26. After 7 years of follow-up, adjuvant pembrolizumab continued to extend disease-free survival and overall survival in high-risk clear-cell renal cell carcinoma. Video published Oct 30, 2026